Cargando…
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, and immunodepression as the main risk factors. In most cases, these malignancies arise in the head and neck area, and they can be tr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013465/ https://www.ncbi.nlm.nih.gov/pubmed/36925925 http://dx.doi.org/10.3389/fonc.2023.1111146 |
_version_ | 1784906802818711552 |
---|---|
author | Colombo, Elena Gurizzan, Cristina Ottini, Arianna Caspani, Francesca Bergamini, Cristiana Locati, Laura D. Marchiselli, Chiara Alberti, Andrea Lorini, Luigi Licitra, Lisa F. Bossi, Paolo Resteghini, Carlo |
author_facet | Colombo, Elena Gurizzan, Cristina Ottini, Arianna Caspani, Francesca Bergamini, Cristiana Locati, Laura D. Marchiselli, Chiara Alberti, Andrea Lorini, Luigi Licitra, Lisa F. Bossi, Paolo Resteghini, Carlo |
author_sort | Colombo, Elena |
collection | PubMed |
description | Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, and immunodepression as the main risk factors. In most cases, these malignancies arise in the head and neck area, and they can be treated with locoregional therapies. A minority of cases require systemic therapy. Currently, Sonic Hedgehog inhibitors (i.e., vismodegib and sonidegib) have been approved for advanced BCC, while the PD-1 checkpoint inhibitor cemiplimab has been approved as a first-line treatment for cSCC and as a second-line treatment for BCC. Nevertheless, there is a clinical need for an effective and safe systemic therapies for advanced synchronous (syn) BCC/cSCC not amenable to local treatments. International guidelines do not provide specific recommendations for patients affected by this condition, and no case reports on the full-dose association of these medications have been previously reported. Here, we present the cases of two elderly patients affected by synBCC/cSCC of the head and neck, who received combined therapy with cemiplimab and sonidegib at full dose and standard schedule, achieving remarkable clinical benefit and long-term responses, without major adverse events. The instance of a feasible treatment for patients with advanced synBCC/cSCC will become increasingly frequent with the advancement of life expectancy in the global population, and the synergistic activity of targeted therapies and immunotherapy—administered either in association or sequentially—deserves to be further explored. |
format | Online Article Text |
id | pubmed-10013465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100134652023-03-15 The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports Colombo, Elena Gurizzan, Cristina Ottini, Arianna Caspani, Francesca Bergamini, Cristiana Locati, Laura D. Marchiselli, Chiara Alberti, Andrea Lorini, Luigi Licitra, Lisa F. Bossi, Paolo Resteghini, Carlo Front Oncol Oncology Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, and immunodepression as the main risk factors. In most cases, these malignancies arise in the head and neck area, and they can be treated with locoregional therapies. A minority of cases require systemic therapy. Currently, Sonic Hedgehog inhibitors (i.e., vismodegib and sonidegib) have been approved for advanced BCC, while the PD-1 checkpoint inhibitor cemiplimab has been approved as a first-line treatment for cSCC and as a second-line treatment for BCC. Nevertheless, there is a clinical need for an effective and safe systemic therapies for advanced synchronous (syn) BCC/cSCC not amenable to local treatments. International guidelines do not provide specific recommendations for patients affected by this condition, and no case reports on the full-dose association of these medications have been previously reported. Here, we present the cases of two elderly patients affected by synBCC/cSCC of the head and neck, who received combined therapy with cemiplimab and sonidegib at full dose and standard schedule, achieving remarkable clinical benefit and long-term responses, without major adverse events. The instance of a feasible treatment for patients with advanced synBCC/cSCC will become increasingly frequent with the advancement of life expectancy in the global population, and the synergistic activity of targeted therapies and immunotherapy—administered either in association or sequentially—deserves to be further explored. Frontiers Media S.A. 2023-02-28 /pmc/articles/PMC10013465/ /pubmed/36925925 http://dx.doi.org/10.3389/fonc.2023.1111146 Text en Copyright © 2023 Colombo, Gurizzan, Ottini, Caspani, Bergamini, Locati, Marchiselli, Alberti, Lorini, Licitra, Bossi and Resteghini https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Colombo, Elena Gurizzan, Cristina Ottini, Arianna Caspani, Francesca Bergamini, Cristiana Locati, Laura D. Marchiselli, Chiara Alberti, Andrea Lorini, Luigi Licitra, Lisa F. Bossi, Paolo Resteghini, Carlo The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports |
title | The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports |
title_full | The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports |
title_fullStr | The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports |
title_full_unstemmed | The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports |
title_short | The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports |
title_sort | association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: two case reports |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013465/ https://www.ncbi.nlm.nih.gov/pubmed/36925925 http://dx.doi.org/10.3389/fonc.2023.1111146 |
work_keys_str_mv | AT colomboelena theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT gurizzancristina theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT ottiniarianna theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT caspanifrancesca theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT bergaminicristiana theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT locatilaurad theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT marchisellichiara theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT albertiandrea theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT loriniluigi theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT licitralisaf theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT bossipaolo theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT resteghinicarlo theassociationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT colomboelena associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT gurizzancristina associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT ottiniarianna associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT caspanifrancesca associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT bergaminicristiana associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT locatilaurad associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT marchisellichiara associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT albertiandrea associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT loriniluigi associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT licitralisaf associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT bossipaolo associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports AT resteghinicarlo associationofcemiplimabplussonidegibforsynchronouscutaneoussquamouscellcarcinomaandbasalcellcarcinomaoftheheadandnecktwocasereports |